Liquidia Corporation, a Morrisville, North Carolina-based biopharmaceutical company, announced on October 13, 2026 a global settlement agreement with United…

HC Wainwright upped their target price on Liquidia from $58.00 to $65.00 and gave the company a "buy" rating in a research report on Thursday.

The agreement resolves all six ongoing lawsuits between Liquidia, United Therapeutics and related parties.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Lifesci Capital raised shares of Liquidia from a "market perform" rating to an "outperform" rating and set a $59.00 price objective on the stock in a research report on Wednesday.

Liquidia stock rallies on a settlement with United Therapeutics. But is it already too late to invest in LQDA shares?

Liquidia Corporation (NASDAQ:LQDA - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock traders acquired 30,594 call options on the company. This represents an increase of approximately 108% compared to the typical volume of 14,708 call options.

Liquidia (LQDA) said late Tuesday it ended all six pending lawsuits with United Therapeutics (UTHR)

Liquidia Corporation shares surged more than 40% in after-hours trading after the company announced a $380.7 million global settlement with United…